Collaborative Models for Strengthening Pharmaceutical Regulation in Africa: Lessons from Egypt's Milestone Achievement

Egypt’s achievement of Maturity Level 3 (ML3) for medical products, as assessed by the WorldHealth Organization’s (WHO) Global Benchmarking Tool (GBT), highlights a significantmilestone in Africa’s pharmaceutical regulation landscape. This paper explores the collaborativestrategies employed by the Egyptian Drug Authority (EDA), including partnerships with theWHO and industry stakeholders, to strengthen local manufacturing and regulatory frameworks.Additionally, it examines the challenges faced by African National Regulatory Authorities(NRAs), such as limited autonomy, resource constraints, and disjointed regulatory systems. Thepaper concludes with recommendations for fostering regulatory harmonization, enhancingautonomy, and leveraging WHO initiatives to strengthen pharmaceutical regulations andimprove health outcomes across Africa.